DECIPHERA PHARMACEUTICALS IN's ticker is DCPH and the CUSIP is 24344T101. A total of 90 filers reported holding DECIPHERA PHARMACEUTICALS IN in Q2 2018. The put-call ratio across all filers is - and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $19,534,000 | -4.8% | 342,274 | -14.4% | 0.05% | -20.0% |
| Q3 2020 | $20,520,000 | -10.7% | 399,999 | +3.9% | 0.06% | -18.8% |
| Q2 2020 | $22,981,000 | +41.7% | 384,805 | -2.3% | 0.08% | +11.1% |
| Q1 2020 | $16,222,000 | -55.9% | 394,020 | -33.3% | 0.07% | -41.5% |
| Q4 2019 | $36,786,000 | +226.1% | 591,037 | +77.9% | 0.12% | +223.7% |
| Q3 2019 | $11,279,000 | +41.1% | 332,320 | -6.3% | 0.04% | +46.2% |
| Q2 2019 | $7,994,000 | +11.8% | 354,503 | +15.0% | 0.03% | +8.3% |
| Q1 2019 | $7,151,000 | +44.0% | 308,132 | +30.2% | 0.02% | +33.3% |
| Q4 2018 | $4,966,000 | -64.6% | 236,607 | -34.6% | 0.02% | -53.8% |
| Q3 2018 | $14,018,000 | -0.7% | 362,024 | +1.0% | 0.04% | -4.9% |
| Q2 2018 | $14,110,000 | +101.0% | 358,585 | +2.4% | 0.04% | +95.2% |
| Q1 2018 | $7,020,000 | +14.6% | 350,331 | +29.7% | 0.02% | +23.5% |
| Q4 2017 | $6,124,000 | +79.2% | 270,124 | +50.1% | 0.02% | +70.0% |
| Q3 2017 | $3,418,000 | – | 180,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| New Leaf Venture Partners, L.L.C. | 1,209,571 | $18,687,872 | 15.44% |
| Redmile Group, LLC | 5,582,105 | $86,243,522 | 3.74% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 5,218,638 | $80,627,957 | 1.80% |
| BRAIDWELL LP | 3,241,351 | $50,078,873 | 1.65% |
| Parkman Healthcare Partners LLC | 491,772 | $7,597,877 | 1.65% |
| Sunesis Advisors, LLC | 96,299 | $1,487,820 | 1.07% |
| ARMISTICE CAPITAL, LLC | 4,100,000 | $63,345,000 | 0.91% |
| Deep Track Capital, LP | 1,363,201 | $21,061,455 | 0.86% |
| AlphaCentric Advisors LLC | 72,500 | $1,120,125 | 0.77% |
| Ikarian Capital, LLC | 174,510 | $2,696,179 | 0.61% |